araag2/HINT huggingface dataset:
Clinical trial NCT00475644 (phase 2, status: completed)
Conditions: lymphoma, follicular
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: enzastaurin
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

        All participants must:

          1. Have had a histologically confirmed diagnosis of Grade 1 or 2 FL, according to World
             Health Organization classification (Harris et al. 1999), at the original time of
             diagnosis. Pathology must be confirmed locally prior to enrollment at the
             investigational site.

          2. Have Ann Arbor Stage III or IV disease.

          3. Must be chemo-naive OR have relapsed disease after receiving only one prior
             chemotherapy regimen. The chemotherapy must have been completed at least 6 months
             prior to first dose of study treatment. Relapse after one prior course of single-agent
             rituximab treatment (in the chemo-naive setting) is also allowed if completed at least
             6 months prior to first dose of study treatment.

          4. Participants must not require cytoreductive therapy for at least 3 months from first
             dose of study treatment, in the opinion of the investigator.

          5. Previous radiation therapy is allowed, but should have been limited and must not have
             included whole pelvis radiation. Participants must have recovered from the toxic
             effects of the treatment prior to study enrollment (except for alopecia). Prior
             radiotherapy must be completed 30 days before study entry. Lesions that have been
             irradiated cannot be included as sites of measurable disease unless clear tumor
             progression has been documented in these lesions since the end of radiation therapy.

        Exclusion Criteria:

        Participants will be excluded from the study if they meet any of the following criteria:

          1. Are unable to swallow tablets.

          2. Are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.

          3. Are receiving concurrent administration of any other antitumor therapy.

          4. Are pregnant or breastfeeding.

          5. Have a serious concomitant systemic disorder (including active bacterial, fungal, or
             viral infection) that, in the opinion of the investigator, would compromise the
             participant's ability to adhere to the protocol.
Clinical trial NCT02544789 (phase 2, status: completed)
Conditions: acute lymphoblastic leukemia
ICD codes: C91.01, C91.02, C91.00
Drugs: clofarabine
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Pediatric patients (younger than 21 years old) with acute lymphoblastic leukemia
             confirmed by histology

          -  Refractory or relapsed acute lymphocytic leukemia who had received at least two drugs
             treatment

          -  No prior chemotherapy within 2 weeks before entry and resolution of toxic effects from
             prior therapy

          -  Normal cardiac function, adequate hepatic function [total bilirubin ≤1.5× upper limit
             of normal (ULN), aspartate aminotransferase (AST) alanine aminotransferase (ALT) ≤
             3ULN] and renal function (serum creatinine ≤ 2 ULN)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Life expectancy more than 3 months

        Exclusion Criteria:

          -  AEs not recovered from prior therapy

          -  Within 3 months from allogeneic or autologous stem cell transplantation

          -  With central nervous involvement or uncontrolled infection

          -  Patients who used clofarabine before or allergic to fludarabine or cladribine
Clinical trial NCT00687193 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, cp-690,550, cp-690,550, cp-690,550, cp-690,550, cp-690,550
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have failed an adequate trial of therapy with at least 1 DMARD due to
             lack of efficacy or toxicity.

        Exclusion Criteria:

          -  Current therapy with any DMARD
Clinical trial NCT00543959 (phase 2, status: terminated)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mk0533, comparator: placebo (unspecified), comparator: pioglitazone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Reason stopped: 
    this study is being discontinued based on data suggesting that none of the doses tested
    demonstrated both glycemic & body fluid benefits vs. the comparitor
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients between the ages of 18 to 70 years with Type 2 diabetes who have not been
             able to adequately control their blood glucose levels

          -  Note: Only patients who have not been taking any antihyperglycemic medicine for 3
             months will be screened

        Exclusion Criteria:

          -  Patients taking any medicines that affect body fluid level such as a diuretic or water
             pill

          -  Patients taking niacin or other certain medications

          -  Patients with any of the following conditions: liver or kidney disease, poorly
             controlled high blood pressure, heart disease or certain blood disorders

          -  Patients with abnormal laboratory results from a blood test that will be given before
             each patient starts the study
Clinical trial NCT00501644 (phase 2, status: completed)
Conditions: ovarian cancer, fallopian tube cancer, peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: carboplatin, gm-csf (sargramostim), interferon gamma
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with Müllerian carcinomas (primary epithelial ovarian, primary peritoneal, or
             fallopian tube) who have had a response to platinum-based chemotherapy and have a
             chemotherapy treatment-free interval of at least 6 months. These patients are
             designated potentially platinum-sensitive.

          2. Measurable disease by radiological or clinical examination parameters.

          3. No prior immunotherapy.

          4. No concurrent steroids or radiation therapy.

          5. Adequate hematological parameters (ANC >/= 1500 cells/UL, platelets >/= 100,000
             cells/UL

          6. Adequate renal function (serum creatinine </= 1.5 mg/dl)

          7. Adequate hepatic function (serum bilirubin </= 1.5 mg/dl)

          8. SGOT or SGPT </= 2.5 normal

          9. Zubrod status </= 2

         10. Signed informed consent

         11. Patients with no more than 2 prior therapy regimens (1st line platinum and platinum
             reinduction will count as one)

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Patients with brain metastases

          3. Serum albumin <3 gm/dl

          4. Weight loss >10% over 4 months

          5. Radiation therapy to whole abdomen

          6. History of clinical or EKG findings suggestive of active (within the last 6 months)
             heart disease

          7. Patients with active autoimmune or inflammatory bowel disease

          8. Patients with an active serious infection or other serious underlying medical
             condition that would otherwise impair their ability to receive protocol treatment.

          9. Dementia or significantly altered mental status that would prohibit the understanding
             and/or giving of informed consent.

         10. Patients with prior hypersensitivity to platinum agents

         11. Patients with history of other malignancy, with the exception of non-melanomatous skin
             cancer; unless in complete remission and off therapy for a minimum of 5 years.
Clinical trial NCT00170677 (phase 2, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: topotecan, topotecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients with histologically-confirmed ovarian cancer

          -  relapse within 6 month after primary therapy

          -  primary therapy with platin and taxan

          -  ECOG 0-2

          -  >= 18 years

          -  leukocytes >= 3.000/ µl

          -  platelet >= 100.000/ µl

          -  neutrophil >= 1.500/ µl

          -  written informed consent

        Exclusion Criteria:

          -  earlier topotecan therapy

          -  simultaneous or planned radiotherapy

          -  secondary malignancy
Clinical trial NCT01432730 (phase 2, status: completed)
Conditions: chronic cough
ICD codes: R05.3
Drugs: gefapixant, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of cough for more than 8 weeks

          -  Normal chest radiograph

          -  Idiopathic or treatment resistant cough (idiopathic defined as a cough for which no
             objective evidence of an underlying trigger can be determined after investigation or a
             cough that is unresponsive to 8 weeks of targeted treatment for identified underlying
             triggers including reflux disease, asthma and post-nasal drip [treatment-resistant]).

        Exclusion Criteria:

          -  Current smoker

          -  Individuals who have given up smoking within the past 6 months, or those with >20
             pack-year smoking history

          -  Treatment with an angiotensin-converting-enzyme inhibitor (ACE-inhibitor) as the
             potential cause of a participant's cough, or requiring treatment with an ACE-inhibitor
             during the study or within 4 weeks prior to Day 0

          -  Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) <60%
Clinical trial NCT01565395 (phase 2, status: withdrawn)
Conditions: parkinson disease, amyotrophic lateral sclerosis
ICD codes: G20, G12.21
Drugs: incobotulinum toxin a, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    could not recruit als participants, hence als arm discontinued
  
Eligibility criteria:

        Inclusion Criteria: Hypothesis: Xeomin® injections into the parotid and submandibular
        glands are safe and effective in the treatment of troublesome sialorrhea in patients with
        PD/Parkinsonism and ALS.

        Inclusion criteria are as follows:

        For ALS: 1. Patients diagnosed with ALS by el-Escorial Criteria, ages 20-80 with
        troublesome sialorrhea as defined below**.

        For PD/ Parkinsonism: 1. PD, Multiple Systems Atrophy (MSA), or Progressive Supranuclear
        Palsy (PSP) diagnosed by clinical criteria, ages 20-80 with troublesome sialorrhea as
        defined below**.

        **Troublesome sialorrhea is defined as grade 3 or more (grade 3 is marked excess of saliva
        with some drooling) or more on the UPDRS Part 2 Sialorrhea grading scale:[33] (Appendix 1)

        For both groups:

          1. Swallowing function: FOIS scale* 5 or greater (see appendix 1 for scale)

          2. If patients have been treated with other medications for sialorrhea earlier, they
             should be off the medications at least 4 weeks prior to the baseline evaluation.

          3. If they are on other medications for sialorrhea at the time of the baseline
             evaluation, the doses will be held stable throughout the period of the study.

          4. Women of child bearing age will need to be on a reliable method of birth control for
             the duration of the study.

        Exclusion criteria

        For both PD and ALS:

          1. Current use of Coumadin

          2. Concurrent significant medical illness.

          3. History of myasthenia gravis or Lambert-Eaton Syndrome

          4. Ongoing substance abuse

          5. History of unreliable follow-up

          6. Past use of Xeomin® or other botulinum toxin preparations

          7. Cognitive impairment, defined as a score ≤ 23/30 on the Mini Mental Status Exam.
Clinical trial NCT00321815 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: pf-3512676 + erlotinib, erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced, EGFR-positive NSCLC

          -  ECOG Performance Status 0, 1 or 2

          -  Measurable disease

        Exclusion Criteria:

          -  Known CNS metastasis

          -  Pre-existing autoimmune or antibody mediated disease
Clinical trial NCT01220024 (phase 2, status: completed)
Conditions: herniorrhaphy, postoperative pain, inguinal hernia
ICD codes: K40.11, K40.41, K40.01, K40.21, K40.31, K40.91, K40.10
Drugs: bupivacaine collagen sponge, placebo collagen sponge
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Man ≥ 18 years

          -  Body mass index (BMI) ≥ 19 and ≤ 40 kg/m2.

          -  Has a planned unilateral inguinal herniorrhaphy (open laparotomy, tension free
             technique) to be performed according to standard surgical technique under general
             anesthesia.

        Exclusion Criteria:

          -  Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products.

          -  Scheduled for bilateral inguinal herniorrhaphy.

          -  Undergone a prior herniorrhaphy on the side scheduled for repair.

          -  Undergone major surgery within 3 mos of the scheduled herniorrhaphy.

          -  Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.

          -  Concomitantly uses antiarrhythmics (eg, amiodarone, lidocaine), propranolol, or
             strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide
             antibiotics and grapefruit juice).

          -  Used long acting analgesics within 24 hours of surgery. Short acting analgesics such
             as acetaminophen may be used on the day of surgery but are subject to preoperative
             restrictions for oral intake.
Clinical trial NCT01406548 (phase 2, status: completed)
Conditions: osteopenia, osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: bps804, placebo, bps804, placebo, bps804, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women (natural or surgically induced menopause)

          -  Low bone mineral density (BMD), as defined by a T score or equivalent BMD absolute
             value (g/cm2) for lumbar spine of between -2.0 and -3.5, inclusive

          -  Body mass index (BMI) must be within the range of 18 to 35kg/m2. Subjects must weigh
             between 45 and 120kg inclusive to participate.

          -  25-(OH) vitamin D serum level of ≥ 15ng/ml

          -  Serum calcium within normal limits

        Exclusion Criteria:

          -  Subjects with suspected neural foraminal stenosis (e.g., cervical, spinal, lumbar), or
             history of Bell's palsy, cranial nerve disorders, temporomandibular joint and muscle
             disorders.

          -  Subjects who have an increased baseline risk of osteosarcoma: Paget's disease of the
             bone or unexplained and clinically significant elevations of alkaline phosphatase
             and/or subjects who have received radiation therapy involving the skeleton.

          -  Subjects with any known bone diseases other than postmenopausal osteoporosis.

          -  Subjects with a history of an osteoporotic fracture (e.g., vertebral fracture,
             fragility fracture of the wrist, radius, humerus, hip, or pelvis).

          -  Subjects who are regularly using or have regularly used agents affecting bone
             metabolism:

               -  Calcitonin, estrogen, SERMs (raloxifene, Tamoxifen, etc.), Tibolone progestin, or
                  androgens within the last three (3) months prior to screening.

               -  Any oral bisphosphonate, lithium chloride, fluoride or systemic
                  glucocorticosteroids (p.o. or i.v.) where the total dose exceeds 750 mg of
                  prednisone or equivalent within the last year prior to screening.

               -  Any previous use of denusomab (ProliaTM), parathyroid hormone (ForteoTM), and/or
                  PTH analogs, strontium ranelate, or parenteral formulations of bisphosphonates.

          -  Current disease(s) known to influence calcium metabolism including
             hyperparathyroidism, hypoparathyroidism, hypocalcemia or hypercalcemia.

          -  Any disease, abnormality or deformation of the spine (e.g., scoliosis, ankylosing
             spondylitis, osteophytes) or hip (e.g., joint prosthesis) which would preclude the
             proper acquisition of a lumbar spine DXA (L1-L4) or femur DXA, respectively.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00357110 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant, anastrozole
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women with hormone receptor-positive early breast cancer and a positive
             Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior
             to randomisation

        Exclusion Criteria:

          -  Inflammatory and/or metastatic breast cancer.

          -  Current or previous malignancy within previous 5 years (other than Breast cancer or
             adequately treated non-melanoma skin cancer or in-situ cervical cancer).

          -  History of bleeding diathesis.
Clinical trial NCT00191373 (phase 2, status: completed)
Conditions: breast neoplasms, cancer of the breast, breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed invasive breast cancer,
             with stage IV disease

          -  Tumors tested by IHC must be 3+ positive for HER2 overexpression. Tumors tested by
             FISH must be positive by the specific FISH assay for genetic amplification of HER2.
             Tumors that are 3+ by IHC but negative by FISH assay are ineligible

          -  Patients must have measurable disease

          -  Patients may NOT have received prior chemotherapy or prior trastuzumab therapy for
             metastatic breast cancer.

          -  Patients may have received prior chemotherapy and/or hormonal therapy for early stage
             breast cancer, including taxane-based chemotherapy regimens. Patients may NOT have
             received trastuzumab in the adjuvant setting unless disease free interval from
             completion of trastuzumab to time of relapse is greater than 12 months.

        Exclusion Criteria:

          -  Patients who have had prior gemcitabine chemotherapy and adjuvant trastuzumab and had
             less than 12- month disease free interval

          -  Patients with known leptomeningeal carcinomatosis
Clinical trial NCT00437294 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: enzastaurin, placebo, capecitabine
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Have been diagnosed with metastatic or recurrent breast cancer.

          -  Have been previously treated with both an anthracycline and a taxane.

          -  Have not received more than two prior chemotherapy treatment programs.

          -  Have stopped any antitumoral hormonal treatment before you enroll in this study.

          -  Have a negative pregnancy blood test if menstruating or capable of becoming pregnant.
             You must use an approved birth control method during the study and for 3 months after
             stopping study treatment.

        Exclusion Criteria:

          -  Cannot follow the study procedures (for example, you cannot swallow tablets).

          -  Are receiving another treatment for your cancer.

          -  Have received another experimental drug in the last 4 weeks.

          -  Have had serious heart disease within last 6 months.

          -  Are pregnant or breast-feeding.
Clinical trial NCT00208260 (phase 2/phase 3, status: completed)
Conditions: colorectal cancer, liver metastases, chemotherapy
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0, D61.810, Z51.11, D64.81, D70.1, Z92.21, P04.11, T80.810S
Drugs: folfiri, folfox-4, folfiri-hd, folfox-7, folfirinox
SMILES: FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the colon or rectum without previous
             resection, or clinically asymptomatic (with or without stent)

          -  Hepatic unresectable metastases R0: due to close vascular contact, or due to liver
             remaining mass less than 25 to 30 % of functional liver.

          -  Not optimally resectable metastases

          -  Extra-hepatic disease will be accepted in case of: asymptomatic primary tumour or
             tumor requiring no urgent surgery (in less than 3 months); three of less than three
             lung metastases (thoracic scan diameter less than 2 cm) and potentially respectable.

          -  Synchronous and metachronous hepatic metastases

          -  WHO performance status 0-1

          -  Adjuvant chemotherapy allowed, except oxaliplatin and irinotecan based combination.

          -  No prior treatment of the liver metastases, whatever.

          -  Life expectancy equal or more than 3 months

        Exclusion Criteria:

        -